

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Oral Industry Group Holdings Limited

中國口腔產業集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8406)

VOLUNTARY ANNOUNCEMENT

THE ENTERING INTO OF JOINT VENTURE AGREEMENT AND PROPOSED ESTABLISHMENT OF A JOINT VENTURE

This announcement is made by China Oral Industry Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders (the “**Shareholders**”) and potential investors of the Company with an update on the latest business development of the Group.

JOINT VENTURE AGREEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 10 September 2026 (after trading hours), Shenzhen Herui Jianheng Health Co., Ltd.* (深圳禾瑞健恒健康有限公司) (“**Herui Jianheng**”, a subsidiary of the Company established in the People’s Republic of China (the “**PRC**”)) entered into a joint venture agreement (the “**Joint Venture Agreement**”) with Future Century (Shenzhen) Health Industry Holdings Co., Ltd.* (未來世紀(深圳)健康產業控股有限公司) (“**Future Century**”), pursuant to which both parties agreed to establish a joint venture (the “**Joint Venture**”) in the PRC. The principal terms of the Joint Venture Agreement are set out below.

PARTIES

- (1) Herui Jianheng; and
- (2) Future Century.

To the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, Future Century and its ultimate beneficial owners are independent third parties and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”)).

* For identification purpose only

SUBJECT

The Joint Venture will be established as a limited liability company in Shenzhen, the PRC or such other location within the PRC as otherwise agreed by both parties, in accordance with the PRC laws and the terms of the Joint Venture Agreement. The proposed name of the Joint Venture is Future Century (Shenzhen) Synthetic Biology Co., Ltd.* (未來世紀(深圳)合成生物有限公司), and its final name and registered address shall be subject to the approval and registration by the competent authorities for market regulation of the PRC.

PURPOSE AND BUSINESS OF THE JOINT VENTURE

The parties intend to combine Future Century's resource base in health industry, technical services and information technology with the Group's existing customer resources and relationships, so as to facilitate the Joint Venture in achieving business synergy and carrying out project research, market expansion and customer service focusing on products and services related to the big health industry.

Pursuant to the Joint Venture Agreement, the Joint Venture is proposed to be principally engaged in the sale of SOD (Superoxide Dismutase) synthetic biology series big health products. The actual business scope of the Joint Venture shall be subject to the final approval and registration by the competent authorities for market regulation of the PRC.

CONTRIBUTIONS

Pursuant to the terms of the Joint Venture Agreement, the registered capital of the Joint Venture will be RMB1,000,000. Herui Jianheng and Future Century will contribute RMB510,000 and RMB490,000 in cash respectively, and will hold 51% and 49% of the equity interest in the Joint Venture respectively.

MANAGEMENT OF THE JOINT VENTURE

The Joint Venture will have a board of directors comprising three directors. Pursuant to the Joint Venture Agreement, Herui Jianheng shall be entitled to nominate two directors, and Future Century shall be entitled to nominate one director. The chairman and the legal representative shall be appointed by Herui Jianheng. The Joint Venture will not maintain a supervisory committee but have one supervisor, who shall, in principle, be appointed by Herui Jianheng.

* *For identification purpose only*

REASONS AND BENEFITS

The Group has been actively seeking business opportunities that align with its long-term development direction. The establishment of the Joint Venture will enable the Group to control its overall investment scale while leveraging the respective industrial resources, channels and technical service capabilities of both parties to explore market opportunities for health industry-related products, which will help expand the Group's business scope and revenue streams.

The terms of the Joint Venture Agreement were determined after arm's length negotiations between the parties. The Directors consider that the terms of the Joint Venture Agreement are fair and reasonable, and the entering into of the Joint Venture Agreement and the establishment of the Joint Venture are in the interests of the Company and its Shareholders as a whole.

IMPLICATIONS UNDER THE GEM LISTING RULES

As all of the applicable percentage ratios under Chapter 19 of the GEM Listing Rules in respect of the establishment of the Joint Venture by the Group are below 5%, the entering into of the Joint Venture Agreement and the establishment of the Joint Venture do not constitute a notifiable transaction of the Company and are not subject to the notification, announcement and shareholders' approval requirements under Chapter 19 of the GEM Listing Rules. This announcement is made by the Company on a voluntary basis.

As stated above, Future Century and its ultimate beneficial owners are independent third parties and are not connected persons of the Company; therefore, the entering into of the Joint Venture Agreement and the establishment of the Joint Venture do not constitute a connected transaction of the Company under Chapter 20 of the GEM Listing Rules.

By Order of the Board
China Oral Industry Group Holdings Limited
Yan Ping
Chairlady and executive Director

Hong Kong, 10 September 2026

As at the date of this announcement, the Board comprises Ms. Yan Ping, Mr. Liu Yao Guang, Mr. Xiao Jiansheng and Mr. Huang Chaojie as executive Directors; and Ms. Lian Jingyu, Ms. Tseung Choi Wing Queenie and Mr. Geng Chuan Long as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk on the “Latest Listed Company Information” page for at least 7 days from the date of its posting and on the Company’s website at www.chinaoral.co.